Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference

Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Croci, Diego O, Rabinovich, Gabriel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125380/
https://www.ncbi.nlm.nih.gov/pubmed/25114834
http://dx.doi.org/10.4161/onci.29380
_version_ 1782329771867242496
author Croci, Diego O
Rabinovich, Gabriel A
author_facet Croci, Diego O
Rabinovich, Gabriel A
author_sort Croci, Diego O
collection PubMed
description Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade.
format Online
Article
Text
id pubmed-4125380
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41253802014-08-11 Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference Croci, Diego O Rabinovich, Gabriel A Oncoimmunology Author's View Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade. Landes Bioscience 2014-06-25 /pmc/articles/PMC4125380/ /pubmed/25114834 http://dx.doi.org/10.4161/onci.29380 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Croci, Diego O
Rabinovich, Gabriel A
Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_full Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_fullStr Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_full_unstemmed Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_short Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_sort linking tumor hypoxia with vegfr2 signaling and compensatory angiogenesis: glycans make the difference
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125380/
https://www.ncbi.nlm.nih.gov/pubmed/25114834
http://dx.doi.org/10.4161/onci.29380
work_keys_str_mv AT crocidiegoo linkingtumorhypoxiawithvegfr2signalingandcompensatoryangiogenesisglycansmakethedifference
AT rabinovichgabriela linkingtumorhypoxiawithvegfr2signalingandcompensatoryangiogenesisglycansmakethedifference

Ejemplares similares